Patient radiation dose and lifetime attributable risk of cancer due to ionizing radiation in cardiovascular interventional radiological procedures

IF 1.4 4区 医学 Q4 ENVIRONMENTAL SCIENCES Radioprotection Pub Date : 2022-04-01 DOI:10.1051/radiopro/2022011
M. Jamshidi, A. Keshavarz, A. Karami, Y. Salimi, G. Valizadeh
{"title":"Patient radiation dose and lifetime attributable risk of cancer due to ionizing radiation in cardiovascular interventional radiological procedures","authors":"M. Jamshidi, A. Keshavarz, A. Karami, Y. Salimi, G. Valizadeh","doi":"10.1051/radiopro/2022011","DOIUrl":null,"url":null,"abstract":"The aim of this study is to calculate the patient radiation dose and Lifetime Attributable Risk (LAR) in Cardiovascular Interventional Radiological (CVIR) procedures. The patient population included 327 patients who underwent Coronary Angiography (CA) and Percutaneous Coronary Interventions (PCI). Exposure data were reported for every examination such as Kerma-Area Product (KAP), fluoroscopy time and number of exposures. Organ dose and effective dose were assessed by PCXMC software. LAR values were determined according to BEIR VII report. The mean effective dose per examination in CA is 12.6 mSv for males and 10.25 mSv for females. In PCI, the mean effective dose is 18.06 mSv for males and 22.73 mSv for females. Organs with highest dose are thymus, heart, breast, and lung. The mean of LAR value in CA is 62 and 60 for males and females, respectively. In PCI, the mean of LAR value is 89 and 132 for males and females, respectively. Also, the KAP to effective dose conversion factors (CFKAP-ED) were calculated. CFKAP-ED for CA is 0.249 in males and 0.228 in females, and for PCI is 0.2446 and 0.2316 for males and females, respectively. This study will help better understand the concept of ionizing radiation dose in the CVIR procedures and how the individual patient’s effective dose and LAR can evaluate the cancer risk.","PeriodicalId":21009,"journal":{"name":"Radioprotection","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radioprotection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1051/radiopro/2022011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENVIRONMENTAL SCIENCES","Score":null,"Total":0}
引用次数: 3

Abstract

The aim of this study is to calculate the patient radiation dose and Lifetime Attributable Risk (LAR) in Cardiovascular Interventional Radiological (CVIR) procedures. The patient population included 327 patients who underwent Coronary Angiography (CA) and Percutaneous Coronary Interventions (PCI). Exposure data were reported for every examination such as Kerma-Area Product (KAP), fluoroscopy time and number of exposures. Organ dose and effective dose were assessed by PCXMC software. LAR values were determined according to BEIR VII report. The mean effective dose per examination in CA is 12.6 mSv for males and 10.25 mSv for females. In PCI, the mean effective dose is 18.06 mSv for males and 22.73 mSv for females. Organs with highest dose are thymus, heart, breast, and lung. The mean of LAR value in CA is 62 and 60 for males and females, respectively. In PCI, the mean of LAR value is 89 and 132 for males and females, respectively. Also, the KAP to effective dose conversion factors (CFKAP-ED) were calculated. CFKAP-ED for CA is 0.249 in males and 0.228 in females, and for PCI is 0.2446 and 0.2316 for males and females, respectively. This study will help better understand the concept of ionizing radiation dose in the CVIR procedures and how the individual patient’s effective dose and LAR can evaluate the cancer risk.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心血管介入放射治疗中电离辐射引起的患者辐射剂量和终身归因癌症风险
本研究的目的是计算心血管介入放射(CVIR)手术中患者的辐射剂量和终生归因风险(LAR)。患者群体包括327例接受冠状动脉造影(CA)和经皮冠状动脉介入治疗(PCI)的患者。报告每次检查的暴露数据,如Kerma-Area Product (KAP)、透视时间和暴露次数。采用PCXMC软件测定器官剂量和有效剂量。根据BEIR VII报告确定LAR值。CA每次检查的平均有效剂量为男性12.6毫西弗,女性10.25毫西弗。在PCI中,男性的平均有效剂量为18.06毫西弗,女性为22.73毫西弗。剂量最高的器官是胸腺、心脏、乳房和肺。男性和女性CA的平均LAR值分别为62和60。在PCI中,男性和女性的平均LAR值分别为89和132。并计算KAP与有效剂量转换因子(CFKAP-ED)。CA的CFKAP-ED男性为0.249,女性为0.228,PCI的CFKAP-ED男性为0.2446,女性为0.2316。本研究将有助于更好地理解CVIR程序中电离辐射剂量的概念,以及个体患者的有效剂量和LAR如何评估癌症风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Radioprotection
Radioprotection ENVIRONMENTAL SCIENCES-PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
CiteScore
3.30
自引率
54.50%
发文量
35
审稿时长
>12 weeks
期刊介绍: Radioprotection publishes articles on all aspects of radiological protection, including non-ionising as well as ionising radiations. Fields of interest range from research, development and theory to operational matters, education and training. The very wide spectrum of its topics includes (theoretical and practical aspects): dosimetry, instrument development, specialized measuring techniques, epidemiology, biological effects (in vivo and in vitro) and risk and environmental impact assessments.
期刊最新文献
Young generations facing post-nuclear accident situations: from Chernobyl to Fukushima Le principe de limitation des doses et la tolérabilité du risque radiologique Evaluation of Barium sulfate-copper breast radiation shield for use in thoracic Computed Tomography Examinations Natural radioactivity and radiological hazards assessment in soil samples of Hassan district, Karnataka State, India Balancing precision and safety: the crucial imperative of radiation dose optimization in radiology and the role of certified medical physicists in quality assessment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1